ArticleFrontiers in medicine2026
Differentiating naturally occurring and disease associated autoantibodies in MPO-ANCA vasculitis through immunogenomic and epitope comparisons.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Introduction: ANCAs are diagnostic and pathogenic in ANCA-associated vasculitis however ANCAs can persist or reappear in clinical remission. It is a known phenomenon that naturally occurring autoantibodies, including ANCAs, are also detectable in healthy individuals. That autoantibodies do not directly correlate with clinical disease suggests that characteristics of the autoantibody response, rather than its mere presence, may determine pathogenicity. We aimed to define immunogenomic and epitope-level differences between naturally occurring and disease-associated MPO-ANCA. Methods: Patients with MPO-ANCA vasculitis (active disease and long-term remission off therapy) and healthy individuals were enrolled at a single center. Peripheral blood mononuclear cells were screened using highly sensitive methods to isolate MPO specific B cells from healthy individuals and patients with MPO-ANCA. Sorted cells were expanded in vitro with antigen stimulation, and supernatants were tested for MPO-ANCA IgG. Bulk B cell receptor (BCR) sequencing of heavy and light chains was performed on autoantigen-specific and control B cells. Serum IgG from the same cohort was used to map MPO epitopes using a yeast surface display library of overlapping MPO-derived peptides. Results: We found that autoantigen-specific B cells were present at similar frequencies in patients with active disease, patients in long-term remission off therapy, and healthy individuals. However, only MPO specific B cells from MPO-ANCA patients produced high levels of MPO-ANCA in vitro, whereas MPO specific B cells from healthy individuals did not. MPO specific B cells from patients exhibited shared immunogenomic features such as reduced clonotype diversity and clonal dominance compared with non-MPO B cells, and there was greater overlap in CDR3 sequences. Epitope mapping revealed that healthy individuals had naturally occurring MPO-reactive IgG, however patient IgG conferred distinct MPO epitope signatures. Discussion: Our findings demonstrate that naturally occurring and disease-associated MPO-ANCA differ in both BCR repertoire features and epitope specificity. These data support the concept that immunological remission in MPO-ANCA vasculitis cannot be defined solely by the presence or absence of ANCAs, but depends on qualitative differences in the autoantibody response, including BCR sequence and epitope targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.